Extended antiretroviral treatment interruption in HIV-infected patients with long-term suppression of plasma HIV RNA

HIV Medicine

Volumn 6, Issue 1, 2005, Pages 7-12

  Achenbach, Chad J ^a,b   Till, M ^a   Palella, F J ^a   Knoll, M D ^a   Terp, S M ^a   Kalnins, A U ^a   Murphy, R L ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b NONE   (United States)

Author keywords

Antiretroviral therapy; Chronic HIV; Treatment interruption

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL OBSERVATION; CONTROLLED STUDY; DETERIORATION; DISEASE DURATION; DRUG WITHDRAWAL; FEMALE; FISHER EXACT TEST; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIPODYSTROPHY; LYMPHOCYTE COUNT; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANK SUM TEST; REBOUND; SEX DIFFERENCE; TIME; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CHRONIC DISEASE; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; RNA, VIRAL; VIRAL LOAD;

EID: 13944282291     PISSN: 14642662     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2005.00257.x     Document Type: Article

References (19)

1. Palella FJ, Delaney KM, Moorman AC et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998; 338: 853-860.
2. Ruiz L, Carcelain G, Martinez-Picado J et al. HIV dynamics and T-cell immunity after three structured treatment interruptions in chronic HIV-1 infection. AIDS 2001; 15: F19-F27.
3. Garcia F, Plana M, Ortiz GM et al. The virological and immunological consequences of structured treatment interruptions in chronic HIV-1 infection. AIDS 2001; 15: F29-40.
4. Lori F, Maserati R, Foli A, Seminari E, Timpone J, Lisziewicz J. Structured treatment interruptions to control HIV-1 infection. Lancet 2000; 355: 287-288.
5. Miller V, Sabin C, Hertogs K et al. Virological and immunological effects of treatment interruptions in HIV-1 infected patients with treatment failure. AIDS 2000; 14: 2857-2867.
6. Deeks SG, Wrin T, Liegler T et al. Virologic and immunologic consequences of discontinuing combination antiretroviral drug therapy in HIV infected patients with detectable viremia. N Engl J Med 2001; 344: 472-480.
7. Hance AJ, Lemiale V, Izopet J et al. Changes in human immunodeficiency virus type 1 populations after treatment interruption in patients failing antiretroviral therapy. J Virol 2001; 75: 6410-6417.
8. Mussini C, Bugarini R, Perno CF et al. Kinetics of CD4 cells after discontinuation of antiretroviral therapy in patients with virological failure and a CD4 cell count greater than 500 cells/microl. AIDS 2002; 16: 1551-1554.
9. Tebas P, Henry K, Mondy K et al. Effect of prolonged discontinuation of successful antiretroviral therapy on CD4+ T cell decline in human immunodeficiency virus-infected patients: implications for intermittent therapeutic strategies. J Infect Dis 2002; 186 1198.
10. Chen RY, Westfall AO, Raper JL et al. Immunologic and virologic consequences of temporary antiretroviral treatment interruption in clinical practice. AIDS Res Hum Retroviruses 2002; 18: 909-916.
11. Poulton MB, Sabin CA, Fisher M. Immunological changes during treatment interruption: risk factors and clinical sequelae. AIDS 2003; 17: 126-128.
12. Hatano H, Vogel S, Yoder C et al. Pre-HAART HIV burden approximates post-HAART viral levels following interruption of therapy in patients with sustained viral suppression. AIDS 2000; 14: 1357-1363.
13. Lyles RH, Munoz A, Yamashita TE et al. Natural history of human immunodeficiency virus type 1 viremia after seroconversion and proximal to AIDS in a large cohort of homosexual men. J Infect Dis 2000; 181: 872-880.
14. Mellors JW, Munoz A, Giorgi JV et al. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 1997; 126: 946-954.
15. Tuldra A, Fumaz CR, Ferrer MJ et al. Psychological impact of structured treatment interruptions in patients with prolonged undetectable HIV-1 viral loads. AIDS 2001; 15: 1904-1906.
16. Hatano H, Miller KD, Yoder CP et al. Metabolic and anthropometric consequences of interruption of highly active antiretroviral therapy. AIDS 2000; 14: 1935-1942.
17. Krentz HB, Gill MJ. The impact of health-related quality of life of treatment interruptions in HIV-1 infected patients. AIDS 2003; 17: 631-636.
18. Panel on Clinical Practices for the Treatment of HIV. Guidelines for using antiretroviral agents among HIV-infected adults and adolescents. Recommendations of the Panel on Clinical Practices for Treatment of HIV. Morb Mortal Wkly Rep 2002; 51: 1-55.
19. Pozniak A, Gazzard B, Anderson J et al. British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy. HIV Med Suppl 2003; 1: 1-41.